Literature DB >> 2441354

Suppression of charge movement by calcium antagonists is not related to calcium channel block.

K B Walsh, S H Bryant, A Schwartz.   

Abstract

The calcium channel-inhibiting drugs nitrendipine and diltiazem represent two important classes of organic calcium antagonists. In the present study, the effect of these drugs on calcium currents and charge displacement currents in bullfrog semitendinosus muscle fibers was examined using a vaseline gap voltage clamp. Nitrendipine (10 microM) reduced the quantity of charge that moved both during the ON phase (QON) and the OFF phase (QOFF) of charge movement. This action appeared to be most selective for QON. However, at this same concentration, nitrendipine had no blocking action on inward calcium currents. In contrast to these findings, diltiazem blocked calcium currents in a concentration-dependent manner, while slightly increasing the quantity of charge moved during QON and QOFF. The enhancement of charge movement by diltiazem resulted from two actions. First, diltiazem shifted the voltage-dependence of charge movement to more negative potentials. Second, diltiazem increased the maximum amount of charge moved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441354     DOI: 10.1007/bf00584775

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  16 in total

1.  An improved vaseline gap voltage clamp for skeletal muscle fibers.

Authors:  B Hille; D T Campbell
Journal:  J Gen Physiol       Date:  1976-03       Impact factor: 4.086

2.  Voltage dependent charge movement of skeletal muscle: a possible step in excitation-contraction coupling.

Authors:  M F Schneider; W K Chandler
Journal:  Nature       Date:  1973-03-23       Impact factor: 49.962

3.  Inward calcium current in twitch muscle fibres of the frog.

Authors:  J A Sanchez; E Stefani
Journal:  J Physiol       Date:  1978-10       Impact factor: 5.182

4.  A calcium dependent inward current in frog skeletal muscle fibres.

Authors:  P R Stanfield
Journal:  Pflugers Arch       Date:  1977-04-25       Impact factor: 3.657

Review 5.  Cellular action of calcium channel blocking drugs.

Authors:  A Schwartz; D J Triggle
Journal:  Annu Rev Med       Date:  1984       Impact factor: 13.739

6.  Pharmacological separation of charge movement components in frog skeletal muscle.

Authors:  C L Huang
Journal:  J Physiol       Date:  1982-03       Impact factor: 5.182

7.  Characterization and photoaffinity labeling of receptor sites for the Ca2+ channel inhibitors d-cis-diltiazem, (+/-)-bepridil, desmethoxyverapamil, and (+)-PN 200-110 in skeletal muscle transverse tubule membranes.

Authors:  J P Galizzi; M Borsotto; J Barhanin; M Fosset; M Lazdunski
Journal:  J Biol Chem       Date:  1986-01-25       Impact factor: 5.157

8.  Sodium currents in human skeletal muscle fibers.

Authors:  T E DeCoursey; S H Bryant; R J Lipicky
Journal:  Muscle Nerve       Date:  1982-10       Impact factor: 3.217

9.  Effect of calcium antagonist drugs on calcium currents in mammalian skeletal muscle fibers.

Authors:  K B Walsh; S H Bryant; A Schwartz
Journal:  J Pharmacol Exp Ther       Date:  1986-02       Impact factor: 4.030

10.  Pharmacological studies of charge movement in frog skeletal muscle.

Authors:  C S Hui
Journal:  J Physiol       Date:  1983-04       Impact factor: 5.182

View more
  3 in total

1.  D600 binding sites on voltage-sensors for excitation-contraction coupling in frog skeletal muscle are intracellular.

Authors:  C S Hui
Journal:  J Muscle Res Cell Motil       Date:  1990-12       Impact factor: 2.698

2.  Contractile properties of frog twitch fibres after D600 paralysis.

Authors:  C S Hui
Journal:  J Muscle Res Cell Motil       Date:  1989-12       Impact factor: 2.698

Review 3.  Reciprocal dihydropyridine and ryanodine receptor interactions in skeletal muscle activation.

Authors:  Christopher L-H Huang; Thomas H Pedersen; James A Fraser
Journal:  J Muscle Res Cell Motil       Date:  2011-10-13       Impact factor: 2.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.